Abstract
In the last several years, bone tumor related microRNA research showed an explosive growth. MicroRNA was found to have a high or low expression level in bone tumor tissue and some microRNAs proved to be the biomarker for poor prognosis. The majority of research was focused on osteosarcoma and Ewing sarcoma. Many tumor associated molecules, including oncogenes and tumor suppressor genes, were found to be the direct targets for microRNA, and enhanced microRNA may play the regulatory role in tumor development. In the bone tumor cell lines, overexpression of microRNA could promote or inhibit the tumor growth, migration, invasion, and metastasis, especially for osteosarcoma and Ewing sarcoma. Many key molecules proved important for tumor genesis were found directly binding to the related microRNA, and whose expression level was down regulated. This may provide a novel therapeutic target for bone tumor. Large scale clinical samples detection and high through-put microarray assay have demonstrated microRNA might be applied to predict and diagnose the bone tumor. MicroRNA in serum was also proved significant as a biomarker for bone tumor.
Keywords: Bone tumor, Ewing sarcoma, microRNA, osteosarcoma.
Current Signal Transduction Therapy
Title:MicroRNA and Bone Tumor: To Up Date
Volume: 9 Issue: 3
Author(s): Huichao Wang, Ruiqiang Zhang, Yudong Jia, Xiaodong Zhang, Yingjie Zhu, Ying Zhang, Xiantao Chen, Xiaoqiang Zhang, Litao Cai, Hanzheng Zhao, Wuyin Li and Youwen Liu
Affiliation:
Keywords: Bone tumor, Ewing sarcoma, microRNA, osteosarcoma.
Abstract: In the last several years, bone tumor related microRNA research showed an explosive growth. MicroRNA was found to have a high or low expression level in bone tumor tissue and some microRNAs proved to be the biomarker for poor prognosis. The majority of research was focused on osteosarcoma and Ewing sarcoma. Many tumor associated molecules, including oncogenes and tumor suppressor genes, were found to be the direct targets for microRNA, and enhanced microRNA may play the regulatory role in tumor development. In the bone tumor cell lines, overexpression of microRNA could promote or inhibit the tumor growth, migration, invasion, and metastasis, especially for osteosarcoma and Ewing sarcoma. Many key molecules proved important for tumor genesis were found directly binding to the related microRNA, and whose expression level was down regulated. This may provide a novel therapeutic target for bone tumor. Large scale clinical samples detection and high through-put microarray assay have demonstrated microRNA might be applied to predict and diagnose the bone tumor. MicroRNA in serum was also proved significant as a biomarker for bone tumor.
Export Options
About this article
Cite this article as:
Wang Huichao, Zhang Ruiqiang, Jia Yudong, Zhang Xiaodong, Zhu Yingjie, Zhang Ying, Chen Xiantao, Zhang Xiaoqiang, Cai Litao, Zhao Hanzheng, Li Wuyin and Liu Youwen, MicroRNA and Bone Tumor: To Up Date, Current Signal Transduction Therapy 2014; 9 (3) . https://dx.doi.org/10.2174/1574362410666150116235118
DOI https://dx.doi.org/10.2174/1574362410666150116235118 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Novel Polymer-Ceramics for Bone Repair and Regeneration
Recent Patents on Biomedical Engineering (Discontinued) Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo
Anti-Cancer Agents in Medicinal Chemistry Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry Case Report of a Large Rhinolith Cast – A Frequently Missed Diagnosis
New Emirates Medical Journal Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases
Current Topics in Medicinal Chemistry Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma
Current Molecular Medicine Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Genomic Approaches and Oxygen Radical Measurement as Biomarker Candidates of Off-Season Predictor of Pollinosis: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets